In the BioHarmony Drug Report Database

"Preview" Icon

Ixekizumab

Taltz (ixekizumab) is an antibody pharmaceutical. Ixekizumab was first approved as Taltz on 2016-03-22. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. The pharmaceutical is active against interleukin-17A.

 

Trade Name

 

Taltz
 

Common Name

 

ixekizumab
 

ChEMBL ID

 

CHEMBL1743034
 

Indication

 

psoriasis
 

Drug Class

 

Monoclonal antibodies: humanized, interleukins as target

Image (chem structure or protein)

Ixekizumab structure rendering